Upregulated Solute Carrier Family 37 Member 1 in Colorectal Cancer is Associated with Poor Patient Outcome and Metastasis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Feb 14

PMID 29434906

Citations 6

Authors

Daiki Kikuchi

Motonobu Saito

Katsuharu Saito

Yohei Watanabe

Yoshiko Matsumoto

Yasuyuki Kanke

Hisashi Onozawa

Suguru Hayase

Wataru Sakamoto

Teruhide Ishigame

Tomoyuki Momma

Shinji Ohki

Seiichi Takenoshita

Affiliations

Soon will be listed here.

Abstract

Solute carrier (SLC) drug transporters exchange various molecules without energy from adenosine triphosphate hydrolysis, indicating an association with anticancer drug resistance. However, the expression and role of SLC transporters in malignant tumors has not yet been fully elucidated. Therefore, in the current study, the expression of SLC37A family genes was evaluated in patients with colorectal cancer (CRC), and it was revealed that SLC family 37 member 1 (SLC37A1) expression was significantly increased in tumorous tissues compared with that in non-tumorous tissues. The cases with upregulated expression of SLC37A1 by immunohistochemical staining were significantly associated with positive venous invasion and liver metastasis. Furthermore, upregulated SLC37A1 expression was associated with poor overall survival time in the present cohort. These results indicated that SLC37A1 is involved in the hematogenous metastasis of CRC. To investigate whether SLC37A1 is associated with hematogenous metastasis and glycolipid metabolism, SLC37A1 was knocked down in colon cancer cells, and the expression of sialyl Lewis A and sialyl Lewis X was observed to be decreased. In summary, upregulation of SLC37A1 was observed in patients with CRC, and was associated with poor patient outcomes and survival. To the best of our knowledge, the present study is the first to propose a key role of SLC37A1 in CRC, and additional studies are warranted to reveal the functional role of SLC37A1 in CRC development.

Citing Articles

Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers.

Bharadwaj R, Jaiswal S, Velarde de la Cruz E, Thakare R Diseases. 2024; 12(3).

PMID: 38534987 PMC: 10968914. DOI: 10.3390/diseases12030063.

Genome-Wide Landscape of North-Eastern European Populations: A View from Lithuania.

Urnikyte A, Molyte A, Kucinskas V Genes (Basel). 2021; 12(11).

PMID: 34828336 PMC: 8623362. DOI: 10.3390/genes12111730.

The Cancer-Associated Antigens Sialyl Lewis and Sd: Two Opposite Faces of Terminal Glycosylation.

DallOlio F, Pucci M, Malagolini N Cancers (Basel). 2021; 13(21).

PMID: 34771437 PMC: 8582462. DOI: 10.3390/cancers13215273.

Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment.

Azwar S, Seow H, Abdullah M, Jabar M, Mohtarrudin N Biology (Basel). 2021; 10(9).

PMID: 34571731 PMC: 8466833. DOI: 10.3390/biology10090854.

SLC34A2 Up-regulation And SLC4A4 Down-regulation Correlates With Invasion, Metastasis, And The MAPK Signaling Pathway In Papillary Thyroid Carcinomas.

Huang F, Wang H, Xiao J, Shao C, Zhou Y, Cong W J Cancer. 2021; 12(18):5439-5453.

PMID: 34405007 PMC: 8364650. DOI: 10.7150/jca.56730.

References

Pan C, Chen S, Jun H, Lin S, Mansfield B, Chou J . SLC37A1 and SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters. PLoS One. 2011; 6(9):e23157. PMC: 3176764. DOI: 10.1371/journal.pone.0023157. View

Szakacs G, Annereau J, Lababidi S, Shankavaram U, Arciello A, Bussey K . Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004; 6(2):129-37. DOI: 10.1016/j.ccr.2004.06.026. View

Shukla S, Chen Z, Ambudkar S . Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat. 2012; 15(1-2):70-80. PMC: 3348341. DOI: 10.1016/j.drup.2012.01.005. View

Lin L, Yee S, Kim R, Giacomini K . SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015; 14(8):543-60. PMC: 4698371. DOI: 10.1038/nrd4626. View

Bartoloni L, Wattenhofer M, Kudoh J, Berry A, Shibuya K, Kawasaki K . Cloning and characterization of a putative human glycerol 3-phosphate permease gene (SLC37A1 or G3PP) on 21q22.3: mutation analysis in two candidate phenotypes, DFNB10 and a glycerol kinase deficiency. Genomics. 2000; 70(2):190-200. DOI: 10.1006/geno.2000.6395. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Higgins C . Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007; 446(7137):749-57. DOI: 10.1038/nature05630. View

Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L . Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013; 25(1):10-21. PMC: 3555299. DOI: 10.3978/j.issn.1000-9604.2012.12.04. View

Hu T, Li Z, Gao C, Cho C . Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 2016; 22(30):6876-89. PMC: 4974586. DOI: 10.3748/wjg.v22.i30.6876. View

10.

Dean M, Rzhetsky A, Allikmets R . The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11(7):1156-66. DOI: 10.1101/gr.184901. View

11.

Levine A, Puzio-Kuter A . The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010; 330(6009):1340-4. DOI: 10.1126/science.1193494. View

12.

. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. PMC: 3401966. DOI: 10.1038/nature11252. View

13.

Venook A, Weiser M, Tepper J . Colorectal cancer: all hands on deck. Am Soc Clin Oncol Educ Book. 2014; :83-9. DOI: 10.14694/EdBook_AM.2014.34.83. View

14.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

15.

Liang J, Liang Y, Gao W . Clinicopathological and prognostic significance of sialyl Lewis X overexpression in patients with cancer: a meta-analysis. Onco Targets Ther. 2016; 9:3113-25. PMC: 4888715. DOI: 10.2147/OTT.S102389. View

16.

Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S . Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A. 2004; 101(21):8132-7. PMC: 419569. DOI: 10.1073/pnas.0402088101. View

17.

Bartoloni L, Antonarakis S . The human sugar-phosphate/phosphate exchanger family SLC37. Pflugers Arch. 2003; 447(5):780-3. DOI: 10.1007/s00424-003-1105-0. View

18.

Chou J, Mansfield B . The SLC37 family of sugar-phosphate/phosphate exchangers. Curr Top Membr. 2014; 73:357-82. PMC: 4180117. DOI: 10.1016/B978-0-12-800223-0.00010-4. View

19.

Okano M, Kumamoto K, Saito M, Onozawa H, Saito K, Abe N . Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer. Oncol Rep. 2015; 33(3):1064-70. DOI: 10.3892/or.2015.3720. View

20.

Lopez-Lopez E, Ballesteros J, Pinan M, Sanchez de Toledo J, Garcia de Andoin N, Garcia-Miguel P . Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2012; 23(2):53-61. DOI: 10.1097/FPC.0b013e32835c3b24. View